Seshadri Neervannan - Tarsus Pharmaceuticals Chief Officer
| TARS Stock | USD 51.08 1.06 2.03% |
Insider
Seshadri Neervannan is Chief Officer of Tarsus Pharmaceuticals
| Age | 56 |
| Address | 15440 Laguna Canyon Road, Irvine, CA, United States, 92618 |
| Phone | 949 409 1801 |
| Web | https://www.tarsusrx.com |
Latest Insider Transactions
Seshadri Neervannan Latest Insider Activity
Tracking and analyzing the buying and selling activities of Seshadri Neervannan against Tarsus Pharmaceuticals stock is an integral part of due diligence when investing in Tarsus Pharmaceuticals. Seshadri Neervannan insider activity provides valuable insight into whether Tarsus Pharmaceuticals is net buyers or sellers over its current business cycle. Note, Tarsus Pharmaceuticals insiders must abide by specific rules, including filing SEC forms every time they buy or sell Tarsus Pharmaceuticals'shares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Seshadri Neervannan over six months ago Disposition of 4879 shares by Seshadri Neervannan of Tarsus PharmaceuticalsI at 30.6 subject to Rule 16b-3 | ||
Seshadri Neervannan over a year ago Sale by Seshadri Neervannan of 372 shares of Tarsus PharmaceuticalsI |
Tarsus Pharmaceuticals Management Efficiency
The company has return on total asset (ROA) of (0.2726) % which means that it has lost $0.2726 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.5956) %, meaning that it created substantial loss on money invested by shareholders. Tarsus Pharmaceuticals' management efficiency ratios could be used to measure how well Tarsus Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.55 in 2024. Return On Capital Employed is likely to drop to -0.66 in 2024. At this time, Tarsus Pharmaceuticals' Non Current Assets Total are comparatively stable compared to the past year. Non Currrent Assets Other is likely to gain to about 1.6 M in 2024, whereas Total Assets are likely to drop slightly above 165.9 M in 2024.Similar Executives
| Showing other executives | INSIDER Age | ||
| Thomas Templeman | Centessa Pharmaceuticals PLC | 64 | |
| Isabel Aznarez | Stoke Therapeutics | 52 | |
| Reid Leonard | Werewolf Therapeutics | 65 | |
| Robert Bazemore | Nuvation Bio | 53 | |
| Sonia DPHIL | PepGen | 38 | |
| Ajim CFA | Monte Rosa Therapeutics | 47 | |
| Caroline Godfrey | PepGen | N/A | |
| MBA MD | Centessa Pharmaceuticals PLC | 51 | |
| Wim Souverijns | Pharvaris BV | 53 | |
| James Goding | Opthea | N/A | |
| FACC MD | Stoke Therapeutics | 61 | |
| Annie Lee | Opthea | N/A | |
| Joshua MBA | Centessa Pharmaceuticals PLC | 50 | |
| Piyush Patel | Tyra Biosciences | 58 | |
| Jeffrey Bornstein | Eledon Pharmaceuticals | N/A | |
| Lynn Scherm | Tyra Biosciences | N/A | |
| Pr Staels | Genfit | 61 | |
| Kathryn Falberg | Nuvation Bio | 60 | |
| Russell MS | Acumen Pharmaceuticals | 66 | |
| Kyle Breidenstine | PepGen | N/A | |
| David Hovland | Eledon Pharmaceuticals | N/A | |
Management Performance
| Return On Equity | -0.6 | ||||
| Return On Asset | -0.27 |
Tarsus Pharmaceuticals Leadership Team
Elected by the shareholders, the Tarsus Pharmaceuticals' board of directors comprises two types of representatives: Tarsus Pharmaceuticals inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Tarsus. The board's role is to monitor Tarsus Pharmaceuticals' management team and ensure that shareholders' interests are well served. Tarsus Pharmaceuticals' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Tarsus Pharmaceuticals' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Jeffrey Farrow, CFO Officer | ||
| Leonard JD, Chief Officer | ||
| Scott Youmans, Vice Sales | ||
| Seshadri Neervannan, Chief Officer | ||
| Adrienne Kemp, Senior Communications | ||
| Elizabeth MD, Chief Director | ||
| Aziz MBA, Chief Officer | ||
| David Nakasone, Head Relations | ||
| Matthew MBA, Vice Marketing | ||
| Michael Ackermann, CoFounder Board | ||
| Jeffrey CPA, CFO Officer | ||
| Bobak MD, President, CoFounder | ||
| Dianne MSW, Chief Officer | ||
| Cara Miller, Senior Affairs | ||
| MD JD, General Secretary |
Tarsus Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Tarsus Pharmaceuticals a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.6 | ||||
| Return On Asset | -0.27 | ||||
| Profit Margin | (1.04) % | ||||
| Operating Margin | (0.52) % | ||||
| Current Valuation | 1.75 B | ||||
| Shares Outstanding | 38.23 M | ||||
| Shares Owned By Insiders | 8.70 % | ||||
| Shares Owned By Institutions | 91.30 % | ||||
| Number Of Shares Shorted | 7.18 M | ||||
| Price To Book | 8.39 X |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Tarsus Stock Analysis
When running Tarsus Pharmaceuticals' price analysis, check to measure Tarsus Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Tarsus Pharmaceuticals is operating at the current time. Most of Tarsus Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Tarsus Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Tarsus Pharmaceuticals' price. Additionally, you may evaluate how the addition of Tarsus Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.